Labs.To
The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications, as well as related healthcare products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications, as well as related healthcare products.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription and over-the-counter medications, as well as related healthcare products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 2.77, supported by CAD 10.81 million in cash and equivalents. However, the company reported negative operating and net income of CAD 8.44 million and CAD 8.27 million, respectively, reflecting a challenging profitability environment.
Profitability metrics show a return on equity of -23.08% and a return on assets of -18.07%, both significantly below the industry median for pharmaceutical companies. These figures suggest the company is underperforming in terms of generating returns for shareholders and utilizing its assets efficiently.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue of CAD 45.12 million is modest compared to industry peers, and there is no indication of significant international operations.
Looking ahead, the company is projected to face continued financial pressure, with a negative operating cash flow of CAD 5.67 million and a free cash flow of CAD 6.71 million. Analysts have issued a single "Hold" recommendation, with no strong buy or sell ratings, suggesting a neutral outlook. The company's capital expenditure of CAD 100,000 indicates minimal investment in growth initiatives.
Risk factors include the company's negative net income and operating income, which could impact its ability to service debt and fund operations. There are no immediate liquidity or dilution flags, and the company has not issued any recent equity or debt offerings that would suggest a high dilution risk. The absence of dilution pressure is a positive sign for shareholders.
Recent events include the company's latest financial filing, which disclosed continued losses and a lack of significant revenue growth. There are no recent earnings call transcripts or press releases indicating major strategic shifts or new product launches. The company's financial performance remains a concern for investors.
- The company has a low debt-to-equity ratio and strong liquidity, but it is reporting negative operating and net income.
- Return on equity and return on assets are significantly below industry medians, indicating poor profitability.
- The company's revenue is concentrated in a single segment with no geographic diversification, increasing risk exposure.
- Analysts have issued a single "Hold" recommendation, with no strong buy or sell ratings, suggesting a neutral outlook.
- The company has no immediate liquidity or dilution risks, but its financial performance remains a concern.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,01 |
| Revenue | —no estimate | —no estimate | 39,0M CAD |
| Operating income | —no estimate | —no estimate | -3,7M CAD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- LABS.TO Market data — financials · 2026-05-28
- Medipharm Labs Corp Market data — analyst estimates · 2026-05-28